<DOC>
	<DOC>NCT00559845</DOC>
	<brief_summary>This single arm study will assess the efficacy and safety of sequential neoadjuvant chemotherapy and Avastin, before surgery and/or radiotherapy, in patients with inflammatory or locally advanced operable breast cancer. Patients will receive FEC, followed by paclitaxel, given concomitantly with Avastin (10mg/kg i.v. every 2 weeks). The anticipated time on study treatment is 3-12 months, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>female patients, &gt;=18 years of age; stage III, or inflammatory breast cancer; ER/PgR positive or negative and HER2 negative; normal LVEF. previous chemotherapy/endocrine therapy; evidence of distant metastatic disease; other primary tumors in last 5 years (except for adequately treated cancer in situ of the cervix, or basal cell skin cancer); chronic daily treatment with &gt;325mg/day aspirin, or &gt;75mg/day clopidogrel.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>